切换至 "中华医学电子期刊资源库"
高级检索
中华肺部疾病杂志(电子版)

中华肺部疾病杂志(电子版) ›› 2020, Vol. 13 ›› Issue (02) : 188 -192. doi: 10.3877/cma.j.issn.1674-6902.2020.02.013

论著

N-乙酰半胱氨酸联合无创正压通气治疗COPD急性发作的临床分析
李中祎1, 张治2,†(), 曹路3, 谭冲1   
  1. 1. 430080　武汉，武汉市第九医院重症医学科
    2. 430050　武汉，武汉市第五医院重症医学科
    3. 443003　宜昌，三峡大学呼吸疾病研究所，宜昌市中心人民医院呼吸与危重症医学科
  • 收稿日期:2019-11-24 出版日期:2020-04-25
  • 通信作者: 张治
  • 基金资助:
    湖北省卫计委面上项目(WJ2019114)

Clinical efficacy of N-acetylcysteine combined with non-invasive positive pressure ventilation on acute exacerbation of chronic obstructive pulmonary disease

Zhongyi Li1, Zhi Zhang2,†(), Lu Cao3, Chong Tan1   

  1. 1. Department of Critical Care Medicine, Wuhan Ninth Hospital, Wuhan 430080, Hubei Province, China
    2. Department of Critical Care Medicine, Wuhan Fifth Hospital, Wuhan 430050, Hubei Province, China
    3. Department of Respiratory and Critical Care Medicine, Institute of Respiratory Diseases, Three Gorges University, Yichang Central People's Hospital, Yichang 443003, Hubei Province, China
  • Received:2019-11-24 Published:2020-04-25
  • Corresponding author: Zhi Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李中祎, 张治, 曹路, 谭冲. N-乙酰半胱氨酸联合无创正压通气治疗COPD急性发作的临床分析[J]. 中华肺部疾病杂志(电子版), 2020, 13(02): 188-192.

Zhongyi Li, Zhi Zhang, Lu Cao, Chong Tan. Clinical efficacy of N-acetylcysteine combined with non-invasive positive pressure ventilation on acute exacerbation of chronic obstructive pulmonary disease[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2020, 13(02): 188-192.

目的

研究N-乙酰半胱氨酸(NAC)联合无创正压通气(NIPPV)治疗慢性阻塞性肺疾病急性发作期(AECOPD)疗效及对患者气道重塑的影响。

方法

选择2016年10月至2019年10月我院AECOPD患者94例，根据治疗方案不同分为观察组53例和对照组41例，均给予激素、抗生素和支气管扩张剂等常规治疗和NIPPV，观察组在此基础上加用NAC雾化吸入，两组疗程均为14 d，比较两组临床疗效及治疗前后患者肺功能、动脉血气、炎症因子和气道重塑指标变化。

结果

观察组和对照组有效率分别为92.45%和82.93%(P>0.05)，两组临床疗效差异无统计学意义(P>0.05)。治疗14 d，两组FEV1、FEV1%和FEV1/FVC明显升高(P<0.05)，且观察组FEV1、FEV1%和FEV1/FVC高于对照组；两组pH和SpO2明显升高(P<0.05)，PaCO2明显降低(P<0.05)，且观察组pH和SpO2高于对照组，PaCO2低于对照组；两组血清TGF-β1、MMP-2和TIMP-2水平明显降低(P<0.05)，且观察组血清TGF-β1、MMP-2和TIMP-2水平低于对照组；差异均有统计学意义(P<0.05)。观察组治疗前后T、WA及WA%均无明显变化(P>0.05)，对照组T、WA及WA%均明显升高(P<0.05)，且观察组T、WA及WA%低于对照组，差异有统计学意义(P<0.05)。

结论

NAC联合NIPPV治疗AECOPD具有良好效果，可有效改善患者肺功能和动脉血气指标，同时还可抑制气道重塑进程，对改善患者预后具有重要意义。

关键词: 肺疾病, 慢性阻塞性, 急性加重期, N-乙酰半胱氨酸, 无创正压通气, 气道重塑
Objective

To study the efficacy of N-acetylcysteine (NAC) combined with non-invasive positive pressure ventilation (NIPPV) on acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and its effects on the airway remodeling of such patients.

Methods

From October 2016 to October 2019, 94 patients with AECOPD in our hospital were divided into an observation group (n=53) and a control group (n=41) according to the different treatment regimens. All the patients were given the conventional treatment such as hormones, antibiotics and bronchodilators and NIPPV, and the observation group was additionally given NAC aerosol inhalation. And the two groups were treated for 14 d. The clinical efficacies and changes in lung function, arterial blood gas, inflammatory factors and airway remodeling before and after treatment were compared between the two groups.

Results

The effective rates in the observation group and the control group were 92.45% and 82.93%, respectively, with no significant difference in the clinical efficacy between the two groups (P>0.05). After 14 d of treatment, the forced expiratory volume in one second (FEV1), FEV1%, and FEV1/the forced vital capacity (FVC) in the two groups were significantly increased (P<0.05), and the FEV1, FEV1% and FEV1/FVC in the observation group were higher than those of the control group. The pH value and the pulse oxygen saturation (SpO2) were significantly increased in the two groups (P<0.05), while the partial pressure of carbon dioxide in artery (PaCO2) was decreased significantly in the two groups (P<0.05), and the pH and SpO2 in the observation group were higher than those of the control group while the PaCO2 in the observation group was lower than that of the control group. The levels of serum transforming growth factor (TGF-β1), MMP-2 and TIMP-2 were significantly reduced in the two groups (P<0.05), and the levels of serum TGF-β1, MMP-2 and TIMP-2 in the observation group were lower than those of the control group (P<0.05). There were no significant changes in T, WA and WA% in the observation group before and after treatment (P>0.05), however, the T, WA and WA% in the control group after treatment were significantly increased after treatment (P<0.05), and the T, WA, and WA% in the observation group were lower than those of the control group (P<0.05).

Conclusion

NAC combined with NIPPV has a good effect on AECOPD. It can effectively improve the lung function and the arterial blood gas indexes of the AECOPD patients, and can also inhibit the process of airway remodeling. Therefore, NAC combined with NIPPV is of great significance for improving the prognosis of AECOPD patients.

Key words: Chronic obstructive pulmonary disease, Acute exacerbation period, N-acetylcysteine, Non-invasive positive pressure ventilation, Airway remodeling
表1 两组治疗前后肺功能比较
分　组 例数 FEV1(L) FEV1%(%) FEV1/FVC(%)
治疗前 治疗后 治疗前 治疗后 治疗前 治疗后
观察组 53 1.54±0.31 1.89±0.42a 57.92±9.08 67.85±8.23a 50.76±8.49 63.87±7.91a
对照组 41 1.48±0.27 1.65±0.36a 58.24±8.71 64.09±8.14a 52.18±8.62 60.25±8.34a
  t值   1.001 2.974 0.174 2.227 0.805 2.159
  P值   0.319 0.004 0.862 0.028 0.423 0.033
表2 两组治疗前后动脉血气指标比较
分　组 例数 pH SpO2(%) PaCO2(mmHg)
治疗前 治疗后 治疗前 治疗后 治疗前 治疗后
观察组 53 7.18±0.25 7.35±0.12 84.03±9.58 93.27±2.96a 54.73±4.86 43.61±3.25a
对照组 41 7.16±0.23 7.32±0.14 82.91±9.72 91.04±3.15a 56.24±4.92 45.98±3.07a
  t值   0.404 1.115 0.563 3.537 1.497 3.634
  P值   0.687 0.268 0.575 0.001 0.138 0.001
表3 两组治疗前后炎症因子比较
分　组 例数 TGF-β1(ng/L) MMP-2(ng/L) TIMP-2(ng/L)
治疗前 治疗后 治疗前 治疗后 治疗前 治疗后
观察组 53 846.39±97.25 504.63±82.71 7.92±1.36 4.07±0.89 2.71±0.65 1.69±0.43
对照组 41 850.12±94.86 592.48±86.04 8.13±1.42 5.24±1.28 2.63±0.62 2.08±0.47
  t值   0.188 5.046 0.732 5.145 0.611 4.197
  P值   0.851 <0.001 0.466 <0.001 0.543 <0.001
表4 两组治疗前后气道重塑指标比较
分　组 例数 T(mm) WA(mm2) WA%
治疗前 治疗后 治疗前 治疗后 治疗前 治疗后
观察组 53 1.02±0.13 1.09±0.15 10.24±0.97 10.82±1.39 62.47±8.14 64.03±8.71
对照组 41 1.04±0.16 1.28±0.17 10.35±1.06 12.78±1.53 63.25±7.96 68.42±9.38
  t值   0.665 5.745 0.525 6.500 0.470 2.351
  P值   0.508 <0.001 0.601 <0.001 0.630 0.021
1
任成山，王关嵩，钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
2
潘东霞，钱一建，王春梅，等. 吸烟与室内空气污染的交互作用对慢性阻塞性肺部疾病影响的分析[J]. 中华流行病学杂志，2016, 37(11): 1444-1449.
3
冯莎莎，陈　炜，张念志，等. 中医药对慢性阻塞性肺疾病气道炎症干预作用研究进展[J]. 辽宁中医药大学学报，2017, 19(9): 104-106.
4
高占成. 从肺功能改善看慢性阻塞性肺疾病的治疗进展[J]. 中华结核和呼吸杂志，2019, 42(4): 314-317.
5
崔俊昌，王方舟. 呼吸道感染所致慢性阻塞性肺疾病急性加重的病原学研究进展[J]. 中华保健医学杂志，2016, 18(6): 514-516.
6
Feng W, Wu X, Li S, et al. Association of serum galectin-3 with the acute exacerbation of chronic obstructive pulmonary disease[J]. Med Sci Monit, 2017, 23: 4612-4618.
7
王晓娟，方向阳. 慢性阻塞性肺疾病全球倡议2019:慢性阻塞性肺疾病诊断、治疗与预防全球策略解读[J]. 中国全科医学，2019, 22(18): 2141-2149.
8
Zhang J, Zheng J, Huang K, et al. Use of glucocorticoids in patients with COPD exacerbations in China: a retrospective observational study[J]. Ther Adv Respir Dis, 2018, 12(9): 175346661876951.
9
谭　杰，罗　鹏，陈宜泰，等. 门诊不同压力无创正压通气对慢性阻塞性肺疾病稳定期合并Ⅱ型呼吸衰竭肺康复影响研究[J]. 中国实用内科杂志，2016, 36(8): 671-674.
10
Aldini G, Altomare A, Baron G, et al. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why[J]. Free Radic Res, 2018, 52(7): 751-762.
11
Xiao G, Lampraki EM, Al-Khalidi S, et al. N-acetylcysteine (NAC) ameliorates Epstein-Barr virus latent membrane protein 1 induced chronic inflammation[J]. Plos One, 2017, 12(12): e0189167.
12
王春彬，张询研，李朋梅，等. N-乙酰半胱氨酸治疗特发性肺纤维化疗效与安全性的Meta分析[J]. 中国药学杂志，2018, 53(11): 931-937.
13
中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007年修订版)[J]. 中华结核和呼吸杂志，2007, 46(1): 8-17.
14
李改平，刘　宇，徐燕杰，等. 沙美特罗替卡松粉吸入剂联合无创正压通气治疗老年慢性阻塞性肺疾病合并呼吸衰竭的临床效果[J]. 中国医药，2017, 12(8): 1153-1156.
15
Mendy A, Forno E, Niyonsenga T, et al. Blood biomarkers as predictors of long-term mortality in COPD[J]. Clin Respir J, 2018, 12(5): 1891-1899.
16
李晓云，纵单单，陈　燕. 慢性阻塞性肺疾病诊断及综合评估[J]. 中国临床医生杂志，2017, 45(9): 4-8.
17
Basso-Vanelli RP, Di LV, Labadessa IG, et al. Effects of inspiratory muscle training and calisthenics-and-breathing exercises in COPD with and without respiratory muscle weakness[J]. Respir Care, 2016, 61(1): 50-60.
18
陈　平，李柳村，罗　红，等. 慢性阻塞性肺疾病急性加重期呼吸支持策略与方式选择[J]. 中华结核和呼吸杂志，2017, 40(12): 887-890.
19
Ni YN, Luo J, Yu H, et al. Can High-flow nasal cannula reduce the rate of endotracheal intubation in adult patients with acute respiratory failure compared with conventional oxygen therapy and noninvasive positive pressure ventilation: a systematic review and Meta-analysis.[J]. Chest, 2017, 151(4): 764-775.
20
Osadnik CR, Tee VS, Carson-Chahhoud KV, et al. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease: a Cochrane review update[J]. Cochrane Database Syst Rev, 2017, 7: CD004104.
21
Wang J, Cui Z, Liu S, et al. Early use of noninvasive techniques for clearing respiratory secretions during noninvasive positive-pressure ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease and hypercapnic encephalopathy: A prospective cohort study[J]. Medicine (Baltimore), 2017, 96(12): e6371.
22
张　媛，刘前桂，赵黎黎，等. 双水平无创正压通气治疗老年慢性阻塞性肺疾病急性加重合并Ⅱ型呼吸衰竭的临床疗效观察[J]. 山西医药杂志，2018, 47(11): 1302-1304.
23
韩　晶，毛锦娟. N-乙酰半胱氨酸对老年慢性阻塞性肺疾病患者肺功能及细胞因子的影响[J]. 临床肺科杂志，2016, 21(6): 1139-1141.
24
朱　洁，马　啸，李泽庚，等. COPD气道重塑与炎症作用机制的研究进展[J]. 中华中医药学刊，2015, 33(3): 546-548.
25
管　频，于化鹏，李　伟，等. 慢性阻塞性肺疾病患者肺组织中核转录因子-κB、转化生长因子-β1表达与气道重塑的关系[J]. 中国老年学杂志，2015, 35(2): 313-314.
[1] 陈腊青, 林佳佳, 毛洪刚, 童冠海, 汪梦娜, 夏红波, 刘卓, 徐海霞, 赵玉华, 张传领. 血清细胞因子及呼出气一氧化氮在哮喘-慢性阻塞性肺疾病重叠综合征中的临床意义[J]. 中华危重症医学杂志(电子版), 2023, 16(04): 316-320.
[2] 周杉京, 诸葛金科, 王芳芳. 补肺活血胶囊对COPD患者cCor、ALD、Ang-Ⅱ的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 517-519.
[3] 吴庆华, 冒勇, 闫效坤. AECOPD并发AKI的危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 529-531.
[4] 芦丹, 杨硕, 刘旭. VEGF、HMGB1、hs-CRP/Alb在AECOPD伴呼吸衰竭中的变化及预后分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 532-534.
[5] 熊锋, 娄建丽. 慢性阻塞性肺疾病急性加重期预后的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 550-553.
[6] 王庆, 张红联, 吴志勇. COPD合并多重耐药菌肺部感染预后危险因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 557-559.
[7] 林静, 陈芳, 刘小霞. COPD患者认知功能障碍影响因素分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 569-571.
[8] 张七妹, 麦宜准, 蒋浩波. 喘可治对慢性阻塞性肺疾病缓解期的临床分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 578-580.
[9] 张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[10] 唐英俊, 李华娟, 王赛妮, 徐旺, 刘峰, 李羲, 郝新宝, 黄华萍. 人脐带间充质干细胞治疗COPD小鼠及机制分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 476-480.
[11] 徐丽玲, 卢玉宝, 赵彦, 任利, 李姝艺, 符娟, 康玲, 汪青松, 尤再春. COPD管理云平台的构建及临床应用[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 481-484.
[12] 李海明, 刘鸿飞, 李俊. 血清脂蛋白酶水平与COPD患者骨骼肌质量减少的关系[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 500-503.
[13] 苏国栋, 王剑桥, 刘洋, 樊祥德, 樊华, 刘惠林. 吸气肌训练对COPD运动恐动症的影响[J]. 中华肺部疾病杂志(电子版), 2023, 16(03): 421-423.
[14] 周婷, 孙培培, 张二明, 安欣华, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病诊断现状调查[J]. 中华临床医师杂志(电子版), 2023, 17(07): 790-797.
[15] 孙培培, 张二明, 时延伟, 赵春燕, 宋萍萍, 张硕, 张克, 周玉娇, 赵璨, 闫维, 吴蓉菊, 宋丽萍, 郭伟安, 马石头, 安欣华, 包曹歆, 向平超. 北京市石景山区40岁及以上居民慢性阻塞性肺疾病患病情况及相关危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(06): 711-719.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号